PharmaShots | Incisive News in 3 Shots

Subscribe Now

Bipolar I Disorder

The US FDA Approves Vanda Pharmaceuticals' Fanapt for Treating Bipolar I Disorder

The US FDA Approves Vanda Pharmaceuticals' Fanapt for Treating Bipolar I Disorder

April 3, 2024

Otsuka and Lundbeck’s Abilify Asimtufii (aripiprazole) Receive the US FDA’s Approval as First Long-Acting Injectable for Schizophrenia or Bipolar I Disorder

Otsuka and Lundbeck’s Abilify Asimtufii (aripiprazole) Receive the US FDA’s Approval as First Long-Acting Injectable for Schizophr...

April 27, 2023

Otsuka and Lundbeck Report the US FDA Acceptance of NDA for Aripiprazole to Treat Schizophrenia and Bipolar I Disorder

Otsuka and Lundbeck Report the US FDA Acceptance of NDA for Aripiprazole to Treat Schizophrenia and Bipolar I Disorder

September 14, 2022

Alkermes Reports Results of Lybalvi in P-IIIb (ENLIGHTEN-Early) Study for the Treatment of Schizophrenia or Bipolar I Disorder

Alkermes Reports Results of Lybalvi in P-IIIb (ENLIGHTEN-Early) Study for the Treatment of Schizophrenia or Bipolar I Disorder

February 9, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us